市場調査レポート
商品コード
1543640
医薬品・バイオテクノロジーにおけるオプションおよび評価取引 (2016~2024年)Option and Evaluation Deals in Pharmaceuticals and Biotechnology 2016-2024 |
医薬品・バイオテクノロジーにおけるオプションおよび評価取引 (2016~2024年) |
出版日: 2024年09月01日
発行: Current Partnering
ページ情報: 英文 750+ Pages
納期: 即日から翌営業日
|
当レポートでは、企業がオプションおよび評価取引に参入する方法と理由を詳細に理解・分析することができます。
当レポートでは、2016年から2024年までのオプションおよび評価取引の詳細情報を掲載しています。
当レポートは、当事者間で発表されたオプション・評価案件の支払条件へのアクセスを提供します。このデータは、支払い条件やその他の取引条件について有益な洞察を提供します。
パートナー候補が交渉した取引条件の柔軟性を理解し、条件交渉中に何を期待できるかについて、交渉プロセスに対する重要な洞察が得られます。多くの中小企業は支払い条項の詳細を求めるでしょうが、支払いがどのように発生し、権利がどのように譲渡されるかという点では、細部が肝要となります。
当レポートでは、2016年以降に発表されたオプション・評価案件について、Current Agreementsの案件・提携データベースに記録されているものを包括的にリストアップし、入手可能な場合には財務条件も記載しているほか、企業とそのパートナーが証券取引委員会に提出した実際のオプション・評価契約文書のオンラインコピーへのリンクも掲載しています。
当レポートでは、読者に以下の主な利点を提供します:
当レポートには以下の情報が含まれます:
当レポートでは、情報が入手可能な取引案件がリストアップされています:
契約合意を分析することで、以下のデューデリジェンスが可能になります:
Option and Evaluation Deals in Pharmaceuticals and Biotechnology provides a detailed understanding and analysis of how and why companies enter option and evaluation deals.
Fully revised and updated, the report provides details of option and evaluation deals from 2016 to 2024.
The report provides access to option and evaluation deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of option and evaluation deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual option and evaluation contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of option and evaluation dealmaking and business activities.
Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in option and evaluation as well as a discussion on the merits of the type of deal.
Chapter 3 provides an overview of the structure of option and evaluation deals.
Chapter 4 provides a review of the leading option and evaluation deals since 2016. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
Chapter 5 provides a comprehensive listing of the top 25 most active option and evaluation dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.
Chapter 6 provides a comprehensive and detailed review of option and evaluation deals organized by company A-Z, therapy, technology and industry type signed and announced since 2016 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the option and evaluation deal.
The deal directory includes a comprehensive listing of all option and evaluation deals announced since 2016. Each listing is organized as a deal directory by company A-Z, therapeutic area and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.
The report also includes numerous table and figures that illustrate the trends and activities in option and evaluation dealmaking since 2016.
In conclusion, this report provides everything a prospective dealmaker needs to know about option and evaluation alliances.
Option and Evaluation Deals in Pharmaceuticals and Biotechnology provides the reader with the following key benefits:
Option and Evaluation Deals in Pharmaceuticals and Biotechnology includes:
In Option and Evaluation Deals in Pharmaceuticals and Biotechnology, the available deals are listed by:
Analyzing contract agreements allows due diligence of: